PL444363A1 - Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji - Google Patents

Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji

Info

Publication number
PL444363A1
PL444363A1 PL444363A PL44436323A PL444363A1 PL 444363 A1 PL444363 A1 PL 444363A1 PL 444363 A PL444363 A PL 444363A PL 44436323 A PL44436323 A PL 44436323A PL 444363 A1 PL444363 A1 PL 444363A1
Authority
PL
Poland
Prior art keywords
pde
preparation
treatment
liquid composition
erectile dysfunction
Prior art date
Application number
PL444363A
Other languages
English (en)
Other versions
PL247528B1 (pl
Inventor
Arkadiusz Szterk
Karol OFIARA
Ilkhom Abdullaev
Dominik MIDAK
Original Assignee
Sativa-Med Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sativa-Med Spółka Akcyjna filed Critical Sativa-Med Spółka Akcyjna
Priority to PL444363A priority Critical patent/PL247528B1/pl
Priority to PCT/PL2024/050028 priority patent/WO2024215214A1/en
Priority to EP24789131.0A priority patent/EP4694865A1/en
Publication of PL444363A1 publication Critical patent/PL444363A1/pl
Publication of PL247528B1 publication Critical patent/PL247528B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem zgłoszenia jest płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5) wybranych z siedenfilu, wardenafilu, ich soli lub ich mieszaniny, sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji, szczególnie jako kompozycja w postaci aerozolu do podawania z atomizera gardłowego o dozie w zakresie 12,5 - 25 mg PDE-5.
PL444363A 2023-04-08 2023-04-08 Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji PL247528B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL444363A PL247528B1 (pl) 2023-04-08 2023-04-08 Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji
PCT/PL2024/050028 WO2024215214A1 (en) 2023-04-08 2024-04-07 Liquid composition of phosphodiesterase type 5 (pde-5) inhibitors, a method of preparation thereof and the use thereof for the treatment of erectile dysfunctions
EP24789131.0A EP4694865A1 (en) 2023-04-08 2024-04-07 Liquid composition of phosphodiesterase type 5 (pde-5) inhibitors, a method of preparation thereof and the use thereof for the treatment of erectile dysfunctions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444363A PL247528B1 (pl) 2023-04-08 2023-04-08 Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji

Publications (2)

Publication Number Publication Date
PL444363A1 true PL444363A1 (pl) 2024-10-14
PL247528B1 PL247528B1 (pl) 2025-07-21

Family

ID=93059742

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444363A PL247528B1 (pl) 2023-04-08 2023-04-08 Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji

Country Status (3)

Country Link
EP (1) EP4694865A1 (pl)
PL (1) PL247528B1 (pl)
WO (1) WO2024215214A1 (pl)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005820A1 (en) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
WO2004019909A2 (en) * 2002-08-29 2004-03-11 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20170216196A1 (en) * 2015-04-03 2017-08-03 Insys Development Company, Inc. Sildenafil sublingual spray formulations
WO2019130052A1 (en) * 2017-12-26 2019-07-04 Ftf Pharma Private Limited Liquid oral formulations for pde v inhibitors
WO2021242913A1 (en) * 2020-05-26 2021-12-02 Strategic Drug Solutions, Inc. Formulations and methods for treating erectile dysfunction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3048501A (en) * 1999-11-18 2001-05-30 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
MX2013001279A (es) * 2013-01-31 2013-08-26 Miguel Angel Garcia Perez Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
EP3277283B8 (en) * 2015-04-03 2021-04-28 Benuvia Therapeutics, LLC Sildenafil sublingual spray formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005820A1 (en) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
WO2004019909A2 (en) * 2002-08-29 2004-03-11 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20170216196A1 (en) * 2015-04-03 2017-08-03 Insys Development Company, Inc. Sildenafil sublingual spray formulations
WO2019130052A1 (en) * 2017-12-26 2019-07-04 Ftf Pharma Private Limited Liquid oral formulations for pde v inhibitors
WO2021242913A1 (en) * 2020-05-26 2021-12-02 Strategic Drug Solutions, Inc. Formulations and methods for treating erectile dysfunction

Also Published As

Publication number Publication date
WO2024215214A1 (en) 2024-10-17
PL247528B1 (pl) 2025-07-21
EP4694865A1 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
PH12021550995A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
GEAP202515878A (en) Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors
PE20220576A1 (es) Inhibidor de egfr para el tratamiento de cancer
PH12022552745A1 (en) [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
MX2022008881A (es) Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico.
MY206578A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CR20210409A (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
AR015595A1 (es) Compuestos derivados de pirazolo [4,3-d]-pirimidin-7-onas, composiciones farmaceuticas, formulacion veterinaria, uso de dichos compuestos en la preparacionde composicion y formulaciones. procedimientos para su uso, compuestos intermediarios, proceso para la preparacion de los compuestos.
MX2025015186A (es) Inhibidores de pi3k y uso de estos
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
MX2023002325A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2024014626A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton
JOP20210153A1 (ar) تركيبة صيدلانية لعلاج ارتفاع ضغط الدم الشرياني الرئوي
WO1994028902A1 (en) Pyrazolopyrimidinones for the treatment of impotence
MX2023010087A (es) Derivados heterociclicos como inhibidores de cinasas jano.
CO6210822A2 (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2
NZ754922A (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
MX2022007009A (es) Composicion topica y metodos de medicion de la capacidad de refrigeracion de una composicion.
MX2025014397A (es) Inhibidores de helicasa de adn recq del sindrome de werner (wrn)
GEAP202516720A (en) Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
CA2677690A1 (en) Treatment of comorbid premature ejaculation and erectile dysfunction
ZA202101688B (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
ES2167555T3 (es) Triazolonas como inhibidores de la sintesis de apolipoproteina-b.
ES2180446A1 (es) Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.